{
    "info": {
        "nct_id": "NCT03976323",
        "official_title": "A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)",
        "inclusion_criteria": "1. Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.\n2. Have stage IV nonsquamous NSCLC.\n3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.\n4. Have measurable disease based on RECIST 1.1.\n5. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.\n\n   Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.\n6. Have a life expectancy of at least 3 months.\n7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.\n8. Have not received prior systemic treatment for their advanced/metastatic NSCLC.\n9. Have adequate organ function.\n10. Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.\n11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Has predominantly squamous cell histology NSCLC.\n2. Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.\n3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.\n4. Has a severe hypersensitivity (â‰¥Grade 3) to pembrolizumab and/or any of its excipients.\n5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.\n6. Has an active autoimmune disease that has required systemic treatment in past 2 years.\n7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n8. Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.\n9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.\n10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.\n11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).\n12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.\n13. Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.\n14. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "8. Have not received prior systemic treatment for their advanced/metastatic NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Have not received prior systemic treatment for their advanced/metastatic NSCLC",
                    "criterion": "prior systemic treatment for advanced/metastatic NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Have stage IV nonsquamous NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "stage IV nonsquamous NSCLC",
                    "criterion": "nonsquamous non-small cell lung cancer (NSCLC)",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": "nonsquamous"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Have measurable disease based on RECIST 1.1.",
            "criterions": [
                {
                    "exact_snippets": "Have measurable disease based on RECIST 1.1.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.",
            "criterions": [
                {
                    "exact_snippets": "Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase.",
                    "criterion": "biopsy specimen adequacy",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation by central laboratory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.",
                    "criterion": "tumor tissue adequacy",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.",
            "criterions": [
                {
                    "exact_snippets": "confirmation that epidermal growth factor receptor (EGFR)...-directed therapy is not indicated",
                    "criterion": "EGFR-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation that...anaplastic lymphoma kinase (ALK)...-directed therapy is not indicated",
                    "criterion": "ALK-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmation that...Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated",
                    "criterion": "ROS1-directed therapy indication",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "assessed within 7 days prior to the administration of study intervention",
                    "criterion": "ECOG performance status assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": "within 7 days prior to the administration of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.",
            "criterions": [
                {
                    "exact_snippets": "Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.",
                    "criterion": "tumor tissue sample",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "sample_type",
                            "expected_value": [
                                "archival tumor tissue sample",
                                "newly obtained core biopsy",
                                "newly obtained incisional biopsy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "tumor lesion not previously irradiated",
                    "criterion": "tumor lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "irradiation_status",
                            "expected_value": "not previously irradiated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Have a life expectancy of at least 3 months.",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of at least 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed diagnosis",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "nonsquamous NSCLC",
                    "criterion": "NSCLC histology type",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "nonsquamous"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Have adequate organ function.",
            "criterions": [
                {
                    "exact_snippets": "adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.",
            "criterions": [
                {
                    "exact_snippets": "Male and female participants who are not pregnant and of childbearing potential",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "adherence to contraceptive guidance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.",
            "criterions": [
                {
                    "exact_snippets": "Male participants must refrain from donating sperm ... during the treatment period and for 180 days afterwards.",
                    "criterion": "sperm donation",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "donation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "during the treatment period and for 180 days afterwards"
                        }
                    ]
                },
                {
                    "exact_snippets": "female participants must refrain from donating eggs to others ... during the treatment period and for 180 days afterwards.",
                    "criterion": "egg donation to others",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "donation",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "during the treatment period and for 180 days afterwards"
                        }
                    ]
                },
                {
                    "exact_snippets": "female participants must refrain from ... freeze/store for her own use during the treatment period and for 180 days afterwards.",
                    "criterion": "egg freezing/storage for own use",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "freeze/store for own use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "during the treatment period and for 180 days afterwards"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "9. Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.",
            "criterions": [
                {
                    "exact_snippets": "Has interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of pneumonitis requiring systemic steroids for treatment",
                    "criterion": "pneumonitis requiring systemic steroids for treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Has received prior therapy with olaparib",
                    "criterion": "prior therapy with olaparib",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy ... with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor",
                    "criterion": "prior therapy with PARP inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Has an active autoimmune disease that has required systemic treatment in past 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Has an active autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "has required systemic treatment in past 2 years",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Has a severe hypersensitivity (â‰¥Grade 3) to pembrolizumab and/or any of its excipients.",
            "criterions": [
                {
                    "exact_snippets": "severe hypersensitivity (â‰¥Grade 3) to pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "severe hypersensitivity (â‰¥Grade 3) to ... any of its excipients",
                    "criterion": "hypersensitivity to pembrolizumab excipients",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.",
            "criterions": [
                {
                    "exact_snippets": "Has completed palliative radiotherapy within 7 days of the first dose",
                    "criterion": "palliative radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "completion timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have recovered from all radiation-related toxicities",
                    "criterion": "radiation-related toxicities",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not require corticosteroids",
                    "criterion": "corticosteroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.",
            "criterions": [
                {
                    "exact_snippets": "Has myelodysplastic syndrome (MDS)",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute myeloid leukemia (AML)",
                    "criterion": "acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "features suggestive of MDS/AML",
                    "criterion": "features suggestive of MDS/AML",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Has predominantly squamous cell histology NSCLC.",
            "criterions": [
                {
                    "exact_snippets": "Has predominantly squamous cell histology NSCLC",
                    "criterion": "NSCLC histology",
                    "requirements": [
                        {
                            "requirement_type": "histological subtype",
                            "expected_value": "predominantly squamous cell"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.",
            "criterions": [
                {
                    "exact_snippets": "Has a known hypersensitivity to any components or excipients of cisplatin",
                    "criterion": "hypersensitivity to cisplatin components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a known hypersensitivity to any components or excipients of ... carboplatin",
                    "criterion": "hypersensitivity to carboplatin components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a known hypersensitivity to any components or excipients of ... pemetrexed",
                    "criterion": "hypersensitivity to pemetrexed components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has a known hypersensitivity to any components or excipients of ... olaparib",
                    "criterion": "hypersensitivity to olaparib components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.",
            "criterions": [
                {
                    "exact_snippets": "Has a diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "is receiving chronic systemic steroid therapy",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.",
            "criterions": [
                {
                    "exact_snippets": "known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known history of hepatitis B infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C virus infection",
                    "criterion": "hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Has known active central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).",
            "criterions": [
                {
                    "exact_snippets": "Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1)",
                    "criterion": "prior therapy with PD-L1 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an agent directed to ... anti PD-L2",
                    "criterion": "prior therapy with anti PD-L2 agent",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Has received prior therapy with an agent ... directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137)",
                    "criterion": "prior therapy with agent directed to stimulatory or co-inhibitory T-cell receptor (CTLA-4, OX-40, CD137)",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.",
            "criterions": [
                {
                    "exact_snippets": "Has a known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that is progressing or has progressed within the past 3 years",
                    "criterion": "additional malignancy progression",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": [
                                "progressing",
                                "has progressed"
                            ]
                        },
                        {
                            "requirement_type": "time_frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring active treatment",
                    "criterion": "additional malignancy treatment requirement",
                    "requirements": [
                        {
                            "requirement_type": "active_treatment_required",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.",
            "criterions": [
                {
                    "exact_snippets": "Has history of a second malignancy",
                    "criterion": "history of a second malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unless potentially curative treatment has been completed with no evidence of malignancy for 2 years",
                    "criterion": "second malignancy after curative treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "potentially curative"
                        },
                        {
                            "requirement_type": "treatment completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "evidence of malignancy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "duration since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}